万维书刊网微信二维码

扫微信,关注编辑QQ!

您的位置:万维书刊网 >>期刊大全 >>SCI/SCIE期刊 >>医药卫生>>药物学

Anti-Cancer Drugs(研究方向:药学) (官网投稿)

简介
Anti-Cancer Drugs(月刊),创刊于1990年,出版国家为美国。Anti-Cancer Drugs报告了与抗癌药物相关的临床和实验结果,并欢迎对抗癌药物设计,药物递送,药理学,激素和生物学方式和化学疗法评估的贡献。专门用于快速出版 抗癌药物创新调查的国际评论杂志旨在刺激和报告有毒和无毒抗癌药物的研究。因此,期刊的范围将涵盖常规细胞毒性化学疗法和激素或生物反应形式如白细胞介素和免疫治疗。
本刊为:SCI期刊(2015-2016), SCIE期刊(2015-2016), 外文期刊,
征稿信息

万维提示:

1、投稿方式:在线投稿。

2、期刊官网:

http://journals.lww.com/anti-cancerdrugs/pages/default.aspx

3、期刊投稿:

http://www.editorialmanager.com/acd/default.aspx

4、信息说明:本刊信息来源于网络,包括 SCI 收录核心期刊,增补期刊,期刊收录数据每年进行更新。本站是公益性网站,为网友投稿提供免费服务,由于受相关约束,我们不能提供相关期刊的影响因子、JCR期刊分区等数据供大家参考,造成不便,敬请谅解。

2017426日星期三

                     

 

Author Guidelines

 

SCOPE

Anti-Cancer Drugs is devoted to the rapid publication of innovative investigations on therapeutic agents against cancer and methods to diminish adverse effects of drugs. The journal publishes peer reviewed articles on anti-cancer drug design, drug delivery, pharmacology and chemotherapy evaluation.

 

Submissions

Authors are strongly encouraged to submit their manuscripts through the web-based tracking system at http://www.editorialmanager.com/acd. The site contains instructions and advice on how to use the system. Authors should NOT in addition then post a hard copy submission to the editorial office, unless you are supplying artwork, letters or files that cannot be submitted electronically, or have been instructed to do so by the editorial office. Should authors have difficulty in uploading files contact the Editor, Dr Mels Sluyser at e-mail: m.sluyser@planet.nl in the first instance, but do not send your files.

 

Double spacing should be used throughout the manuscript, which should include the following sections, each starting on a separate page: Title Page, abstract and keywords, text, acknowledgements, references, individual tables and captions. Margins should be not less than 3 cm. Pages should be numbered consecutively, beginning with the Title Page, and the page number should be placed in the top right hand corner of each page. Abbreviations should be defined on their first appearance in the text; those not accepted by international bodies should be avoided.

Authors are invited to list up to four potential reviewers, including their full addresses, telephone and fax numbers, and e-mail addresses.

 

PRESENTATION OF PAPERS

 

Title Page

The Title Page should carry the full title of the paper and a short title to be used as a ‘running head’ (and which should be so identified). The first name, middle initial and last name of each author should appear. If the work is to be attributed to a department or institution, its full name should be included. Any disclaimers should appear on the Title Page, as should the name and address of the author responsible for correspondence concerning the manuscript and the name and address of the author to whom requests for reprints should be made. Finally, the Title Page should state conflicts of interest and source of funding, and when none state “none declared”.

 

Abstracts

The second page should carry a structured abstract of no more than 250 words. The abstract should state the Objective(s) of the study or investigation, basic Methods (selection of study subjects or laboratory animals; observational and analytical methods), main Results (giving specific data and their statistical significance, if possible), and the principal Conclusions. It should emphasise new and important aspects of the study or observations.

 

Key Words

The abstract should be followed by a list of 3–10 keywords or short phrases which will assist the cross-indexing of the article and which may be published. When possible, the terms used should be from the Medical Subject Headings list of the National Library of Medicine (http://www.nlm.nih.gov/mesh/meshhome.html).

 

Text

Full papers of an experimental or observational nature may be divided into sections headed Introduction, Methods (including ethical and statistical information), Results and Discussion (including a conclusion), although reviews may require a different format.

 

Acknowledgements

Acknowledgements should be made only to those who have made a substantial contribution to the study. Authors are responsible for obtaining written permission from people acknowledged by name in case readers infer their endorsement of data and conclusions.

 

References

References should be numbered consecutively in the order in which they first appear in the text. They should be assigned Arabic numerals, which should be given in brackets, e.g. [17], [17, 19-23]. References should include the names of all authors when six or fewer; when seven or more, list only the first six names and add et al. References should also include full title and source information. Journal names should be abbreviated as in MEDLINE (NLM Catalog, http://www.ncbi.nlm.nih.gov/nlmcatalog).

 

编委会

 

总编辑

Mels Sluyser

博士荷兰癌症研究所H4

Plesmanlaan 121

1066 CX荷兰

阿姆斯特丹

电话:+31 35 52 59 943

m.sluyser@planet.nl 

 

编委会

 

MM阿卜杜勒-拉蒂夫

艾斯尤特,埃及

 

佩雷

马德里,西班牙

 

 

美国俄亥俄州的Almasan Cleveland

 

 

法国巴塞罗那马赛

 

AGBasnakian

小石城,AR,美国

 

TM啤酒

波特兰,OR,美国

 

A.Bishayee

MiamiFLUSA

 

DP Bottaro

BethesdaMD,美国

 

 

荷兰的Boven Amsterdam

 

D. Decaudin

巴黎,法国

 

WA Denny

奥克兰,新西兰

 

JJ Densmore

CharlottesvilleVAUSA

 

P. Dent

RichmondVAUSA

 

J.P。德罗

法国里昂

 

G. Facchini

那不勒斯,意大利


投稿问答最小化  关闭